Is there a Bearish outlook for Loxo Oncology, Inc. (NASDAQ:LOXO) this week?

December 9, 2017 - By Louis Casey

 Is there a Bearish outlook for Loxo Oncology, Inc. (NASDAQ:LOXO) this week?
Investors sentiment increased to 3.83 in 2017 Q2. Its up 1.64, from 2.19 in 2017Q1. It is positive, as 5 investors sold Loxo Oncology, Inc. shares while 18 reduced holdings. 43 funds opened positions while 45 raised stakes. 57.37 million shares or 120.56% more from 26.01 million shares in 2017Q1 were reported.
California State Teachers Retirement Sys holds 35,500 shares. The New Jersey-based Lord Abbett And Limited Co has invested 0.18% in Loxo Oncology, Inc. (NASDAQ:LOXO). Pictet Asset Mgmt Limited holds 0.03% or 210,766 shares in its portfolio. Emory University has 2.42% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Ubs Asset Management Americas invested in 0% or 240,338 shares. Sectoral Asset Management Inc holds 1.95% or 221,795 shares. Fil Ltd has 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Principal Fincl reported 3,664 shares. Royal Comml Bank Of Canada holds 0% or 36 shares. 49,800 are owned by Pointstate Limited Partnership. Grp One Trading Limited Partnership reported 1,200 shares or 0% of all its holdings. Schwab Charles Investment Mgmt accumulated 81,716 shares. Rock Springs Cap Management L P owns 288,000 shares. Tiaa Cref Llc holds 0% or 54,986 shares. Voya Invest Mgmt Ltd Liability Corporation has invested 0.04% in Loxo Oncology, Inc. (NASDAQ:LOXO).

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc had 29 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Thursday, November 16. The stock has “Overweight” rating by Morgan Stanley on Friday, October 6. On Friday, August 28 the stock rating was upgraded by Zacks to “Sell”. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Tuesday, August 8 with “Buy” rating. Jefferies initiated it with “Buy” rating and $50 target in Wednesday, February 8 report. The rating was maintained by Cowen & Co with “Buy” on Monday, June 5. The firm has “Outperform” rating by Cowen & Co given on Thursday, August 27. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Buy” rating given on Friday, October 20 by Citigroup. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 27 report. The rating was maintained by Stifel Nicolaus on Monday, June 5 with “Buy”. Below is a list of Loxo Oncology, Inc. (NASDAQ:LOXO) latest ratings and price target changes.

28/11/2017 Broker: William Blair Rating: Outperform Initiates Coverage On
16/11/2017 Broker: Citigroup Rating: Buy Old Target: $112 New Target: $108 Maintain
14/11/2017 Broker: JMP Securities Rating: Buy New Target: $95.0 Upgrade
14/11/2017 Broker: IFS Securities Old Rating: Outperform New Rating: Strong Buy Upgrade
02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $104.0 Maintain
20/10/2017 Broker: Citigroup Rating: Buy New Target: $112.0 Maintain
06/10/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $95 New Target: $103 Maintain
27/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $94.0 Maintain
29/08/2017 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Perform Downgrade
08/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $94.0000 Maintain

The stock increased 4.42% or $3.52 during the last trading session, reaching $83.15. About 511,141 shares traded or 3.35% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since December 9, 2016 and is uptrending. It has outperformed by 60.42% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $2.49 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Seekingalpha.com which released: “Loxo Oncology Is A Buy Ahead Of Data Update” on December 03, 2017. Also Nasdaq.com published the news titled: “Loxo Oncology Enters Oversold Territory (LOXO)” on November 14, 2017. Globenewswire.com‘s news article titled: “Loxo Oncology Announces Global Development and Commercialization Partnership …” with publication date: November 14, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.